Emerging evidence demonstrated that TLK1 and TLK2 are involved in cancer progression and therapeutic resistance (48–51) and it has been shown that inhibition of TLK potentiates cell-killing in different types of cancers (3,51–57), making TLK1 and 2 attractive targets for therapeutic strategy development. The gene discussed is TLK2; the disease is cancer.